Merck Announces Second-Quarter 2024 Sales and Earnings Conference Call on July 30

MSD, known as Merck outside the United States and Canada, will host its second-quarter 2024 sales and earnings conference call for institutional investors and analysts at 9:00 a.m. ET on Tuesday, July 30. During the call, company executives will provide an overview of Merck’s performance for the quarter.

Investors, journalists, and the general public can access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures, and slides highlighting the results, will also be available on Merck’s website.

Participants may join the call by dialing (800) 779-0641 (U.S. and Canada Toll-Free) or (517) 308-9147 and using the access code 4761229.

At Merck, known as MSD outside the United States and Canada, we are unified around our purpose: leveraging leading-edge science to save and improve lives worldwide. For over 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aim to be the premier research-intensive biopharmaceutical company globally, and we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable, and healthy future for all people and communities. For more information, visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube, and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based on the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry.

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter